Jelle Kijlstra, MD, MBA

Jelle Kijlstra, MD, MBA has a diverse and extensive work experience in the field of medical research and development. Jelle currently holds the position of Chief Medical Officer at SIRPant Immunotherapeutics since July 2023. Prior to this, they served as the Chief Medical Officer at Sound Biologics from April 2020 to June 2023. During their time at Sound Biologics, they successfully filed and received FDA-clearance for two Investigational New Drugs (INDs) in the treatment of solid tumors and B-cell lymphomas/CLL. Jelle also played a key role in managing Phase 1 studies and overseeing the clinical development program, which resulted in the progression of the program from Phase 1 to pivotal Phase 3 within three years.

Before joining Sound Biologics, Jelle held the position of Senior Director, Hematology/Oncology at Covance from March 2016 to March 2020. Jelle'sresponsibilities included overseeing hematology/oncology projects and programs. Prior to Covance, they served as the Vice President of Clinical Research and Development at Atossa Therapeutics, Inc. from May 2014 to January 2016. In this role, they directed the global clinical development program for drugs targeting early stage breast cancer and high-risk pre-cancerous lesions.

Jelle also has experience working with other notable companies in the industry, including Spectrum Pharmaceuticals, where they served as the Vice President of Global Clinical Affairs from July 2010 to January 2014. Jelle also held positions at AngioDynamics as Vice President and Medical Director from February 2005 to September 2008, and at Dendreon as Senior Medical Director from 2000 to 2004. At Dendreon, they played a crucial role in completing and reporting the phase 2 and initial Phase 3 clinical program for a cellular immunotherapy, resulting in FDA approval for the treatment of castrate-resistant prostate cancer.

Jelle'searlier career includes positions at AstraZeneca as a Medical Director from 1995 to 1998, where they collaborated with NCI and FDA on product labeling for tamoxifen in the prevention of breast cancer, and at Procter & Gamble as a Senior Medical Advisor from August 1990 to April 1995. At Procter & Gamble, they conducted clinical development for osteoporosis, Paget's disease, and bone metastases from breast cancer, enrolling over 12,000 patients in six trials.

Jelle Kijlstra's work experience demonstrates their expertise and leadership in advancing clinical development programs, managing global clinical research, and obtaining regulatory approvals for innovative therapies in the field of oncology and related areas.

Jelle Kijlstra, MD, MBA completed their Doctor of Medicine (M.D.) degree in medicine at the University of Amsterdam, from 1979 to 1988. Jelle then pursued further education in the field of Health/Health Care Administration/Management, earning a Master of Business Administration (MBA) degree from Northwestern University - Kellogg School of Management, from 1988 to 1990.